Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.indswiftlabs.com | |
Market Cap | 749.52 Cr. | |
Enterprise Value(EV) | 1,539.39 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 7.49 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 16.94 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.74 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 95.74 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.32 | Calculated using Price: 126.85 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 5.91 Cr. | 59,086,860 Shares |
FaceValue | 10 | |
About Ind-Swift Laboratories Ltd. | ||
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry. |
1 Day |
|
+0.20% |
1 Week |
|
+6.91% |
1 Month |
|
+23.55% |
3 Month |
|
+19.46% |
6 Month |
|
+46.93% |
1 Year |
|
+91.69% |
2 Year |
|
+82.97% |
5 Year |
|
+234.95% |
10 Year |
|
+225.33% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -36.36 | -23.11 | -15.89 | 7.89 | 8.99 | -5.56 | -0.78 | -0.54 | 10.61 | |
Return on Capital Employed (%) | -1.52 | 1.4 | 2.19 | 4.59 | 9.25 | 5.97 | 8.31 | 7.88 | 13.25 | |
Return on Assets (%) | -5.22 | -2.65 | -1.86 | 1.11 | 1.53 | -1.17 | -0.18 | -0.12 | 2.7 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 595 | 517 | 531 | 553 | 588 | 641 | 604 | 601 | 682 | 730 | |
Non Curr. Liab. | 811 | 717 | 495 | 438 | 901 | 828 | 840 | 814 | 741 | 726 | |
Curr. Liab. | 833 | 951 | 1,005 | 936 | 356 | 323 | 315 | 334 | 371 | 322 | |
Minority Int. | 0 | 0 | |||||||||
Equity & Liab. | 2,239 | 2,185 | 2,031 | 1,927 | 1,845 | 1,792 | 1,758 | 1,749 | 1,794 | 1,778 | |
Non Curr. Assets | 1,319 | 1,264 | 1,202 | 1,088 | 1,009 | 929 | 814 | 674 | 630 | 613 | |
Curr. Assets | 920 | 922 | 829 | 839 | 836 | 863 | 942 | 1,073 | 1,163 | 1,165 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,239 | 2,185 | 2,031 | 1,927 | 1,845 | 1,792 | 1,758 | 1,749 | 1,794 | 1,778 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 660 | 653 | 697 | 763 | 757 | 780 | 891 | 1,039 | 1,207 | 1,192 | |
Other Income | 22 | 16 | 23 | 26 | 37 | 33 | 23 | 44 | 34 | 30 | |
Total Income | 683 | 669 | 720 | 788 | 794 | 813 | 914 | 1,082 | 1,241 | 1,222 | |
Total Expenditure | -572 | -546 | -591 | -628 | -630 | -636 | -709 | -843 | -978 | -949 | |
PBIDT | 111 | 123 | 129 | 160 | 163 | 177 | 206 | 239 | 263 | 273 | |
Interest | -117 | -106 | -90 | -35 | -92 | -107 | -100 | -96 | -92 | -84 | |
Depreciation | -84 | -85 | -88 | -87 | -104 | -90 | -87 | -131 | -57 | -50 | |
Taxation | 24 | 24 | 16 | -14 | -21 | -1 | -21 | -15 | -39 | -67 | |
Exceptional Items | -53 | -15 | -5 | -2 | 83 | -27 | -27 | ||||
PAT | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 45 | |
Minority Interest | |||||||||||
Share Associate | 0 | -1 | |||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 44 | |
Adjusted EPS | -29 | -14 | -9 | 5 | 6 | -4 | -1 | 0 | 8 | 7 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 66 | 98 | 79 | 96 | 73 | -64 | 125 | 135 | 150 | 195 | |
Cash Fr. Inv. | -27 | -36 | -30 | -31 | -17 | -12 | -9 | -10 | 5 | -13 | |
Cash Fr. Finan. | -38 | -64 | -48 | -69 | -62 | 100 | -133 | -124 | -141 | -186 | |
Net Change | 0 | -1 | 2 | -4 | -6 | 23 | -17 | 1 | 14 | -4 | |
Cash & Cash Eqvt | 21 | 20 | 22 | 16 | 9 | 30 | 11 | 12 | 26 | 17 |
Mon, 22 Apr 2024
Incorporation-XBRL IND-SWIFT LABORATORIES LIMITED has informed the Exchange regarding Incorporation |
Fri, 19 Apr 2024
Acquisition Ind-Swift Laboratories Limited has informed the Exchange about the Incorporation of a wholly owned subsidiary in Dubai, UAE. |
Mon, 15 Apr 2024
Updates Ind-Swift Laboratories Limited has informed the Exchange regarding 'Statement of Debt Securities/NCD for the period ended March 31, 2024'. |
Thu, 25 Apr 2024 |
Opening at Low |
Making Higher Highs for 3 days |
Close Within 52 Week High Zone |
Making Higher Highs for 2 Days |
High Increase in 1 Month |